Every 8-K that ANI Pharmaceuticals, Inc. (ANIP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIP filings page.
ANI Pharmaceuticals, Inc. (ANIP) reported governance changes, appointing Henry Gosebruch to its Board of Directors effective August 19, 2026, with a term expiring at the 2027 annual meeting of stockholders. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector, including senior roles at Lakefront Biotherapeutics NV, Neumora Therapeutics, AbbVie and J.P. Morgan.
As a non-employee director, he will receive an initial restricted stock award valued at $525,000 under the company’s 2022 Stock Incentive Plan, vesting in three equal annual installments on the first, second and third anniversaries of joining the Board. ANI also disclosed that director Muthusamy “Samy” Shanmugam resigned from the Board effective immediately but will continue in his executive roles as Head of Research and Development and Chief Operating Officer of New Jersey Operations.
ANI Pharmaceuticals reported record second-quarter 2026 results with total net revenues of $266.0 million, up 25.9% year-over-year. Rare Disease revenues rose to $135.8 million, including Cortrophin Gel net revenues of $117.1 million, an increase of 43.5%, while Generics net revenues grew 9.7% to $99.1 million.
GAAP net income available to common shareholders was $24.7 million, or $1.05 per diluted share, compared with $8.1 million and $0.36 a year earlier. Adjusted non-GAAP EBITDA increased 32.4% to $71.6 million and adjusted non-GAAP diluted EPS reached $2.21. The company reaffirmed 2026 guidance for total net revenue of $1,080–$1,140 million and adjusted non-GAAP EBITDA of $285–$300 million, while updating Cortrophin Gel net revenue guidance to $520–$540 million. As of June 30, 2026, ANI held $360.2 million in unrestricted cash and cash equivalents against $620.9 million of principal debt and had a $100.0 million share repurchase program authorized through May 2029.
ANI Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders approved all proposals, including electing seven directors to serve until the 2027 annual meeting and ratifying Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and chose to hold this advisory vote every one year. In addition, they approved the company’s Amended and Restated 2022 Stock Incentive Plan, which governs equity-based compensation, with the full plan text filed as an exhibit.
ANI Pharmaceuticals furnished an updated investor presentation outlining strong growth plans and refreshed 2026 guidance. The company now projects $1.08–$1.14 billion in 2026 total net revenue, implying mid‑20% year-over-year growth, with its Rare Disease business expected to contribute about 60% of sales.
Lead asset Cortrophin Gel is forecast to generate $540–$575 million in 2026 revenue and approximately 60% growth, supported by expansion into acute gouty arthritis flares and other underpenetrated indications. ILUVIEN is guided to $78–$83 million, while Generics continue to provide strong cash flow.
For 2026, ANI targets adjusted non-GAAP EBITDA of $285–$300 million and adjusted non-GAAP diluted EPS of $9.19–$9.69. In Q1 2026, total net revenues reached $237.5 million and adjusted non-GAAP EBITDA was $63.0 million, reflecting solid top- and bottom-line growth. The board also authorized a $100 million share repurchase program, and the company reported cash of $311 million and net leverage of roughly 1.3x as of March 31, 2026.
ANI Pharmaceuticals reported strong first quarter 2026 growth and raised its full-year outlook. Net revenues reached $237.5 million, up 20.5% year-over-year, led by Rare Disease products and Generics. Cortrophin Gel net revenues were $75.1 million, a 42.1% increase, and ILUVIEN net revenues were $19.3 million, up 19.5%, both mainly driven by higher volume.
GAAP net income available to common shareholders rose to $29.5 million, with diluted GAAP EPS of $1.28, while adjusted non-GAAP diluted EPS was $2.05. Adjusted non-GAAP EBITDA grew 24.1% to $63.0 million. The company now guides 2026 total net revenue to $1.08–$1.14 billion and adjusted non-GAAP EBITDA to $285–$300 million, and expects adjusted non-GAAP diluted EPS of $9.19–$9.69.
ANI reaffirmed 2026 Cortrophin Gel net revenue guidance of $540–$575 million and ILUVIEN guidance of $78–$83 million. The board also authorized a $100 million share repurchase program through May 2029, to be funded with the company’s cash resources.
ANI Pharmaceuticals changed its independent auditor. On April 1, 2026, the company dismissed EisnerAmper LLP as its independent registered public accounting firm and, on the same date, the Audit and Finance Committee approved the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2026.
The company states that EisnerAmper’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications. It also reports no disagreements or reportable events with EisnerAmper during those periods, and has filed EisnerAmper’s response letter as an exhibit.
ANI Pharmaceuticals is highlighting strong recent growth and ambitious 2026 goals as it meets institutional investors and updates its investor presentation. Total net revenue reached $883 million in 2025, a 44% year-over-year increase, driven by both rare disease and generics.
Lead rare disease drug Cortrophin Gel generated $348 million in 2025 revenue, up 76%, while ILUVIEN contributed $75 million. Adjusted non-GAAP EBITDA was $230 million, up 47%, and adjusted non-GAAP diluted EPS was $7.89, a 52% increase.
For 2026, the company is guiding to $1.055–$1.115 billion in total net revenue and $275–$290 million in adjusted non-GAAP EBITDA, implying roughly low‑20% growth at the midpoint. Rare disease products are expected to provide about 60% of 2026 revenue, with Cortrophin Gel forecast at $540–$575 million and ILUVIEN at $78–$83 million. Adjusted non-GAAP diluted EPS is projected at $8.83–$9.34 and adjusted gross margin at 59.3%–60.3%.
The strategy centers on accelerating transformation into a leading rare disease company, including a new ~90-person commercial organization for acute gouty arthritis flares and continued investment in Phase 4 trials and real‑world evidence for Cortrophin Gel. The generics segment, with about $384 million in 2025 revenue, remains an important cash generator supported by three U.S. manufacturing sites and a pipeline targeting 10–15 launches annually. Year-end 2025 cash was $286 million with net leverage of about 1.5x, supporting ongoing investment and disciplined capital allocation.
ANI Pharmaceuticals reported record fourth quarter and full-year 2025 results and reaffirmed its 2026 financial guidance. Full-year net revenues reached $883.4 million, up 43.8%, with Q4 revenues of $247.1 million, up 29.6% from 2024.
Rare Disease revenue grew strongly to $422.6 million in 2025, led by Cortrophin Gel at $347.8 million, up 75.6%. GAAP net income available to common shareholders was $77.2 million versus a prior-year loss, and adjusted non-GAAP EBITDA rose to $229.8 million, up 47.3%. 2026 guidance calls for total revenue of $1.055–$1.115 billion and adjusted diluted EPS of $8.83–$9.34. The company ended 2025 with $285.6 million in cash and $629.1 million in principal debt.
ANI Pharmaceuticals, Inc. reported that it has issued a press release with select preliminary unaudited financial results for the fourth quarter and full fiscal year ended December 31, 2025, along with preliminary 2026 financial guidance. These figures are based on management estimates, have not been audited or reviewed by the company’s independent registered public accounting firm, and may change, potentially in a material way.
The company also noted that President & CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with an accompanying investor presentation furnished as an exhibit. The preliminary results and guidance, as well as the presentation materials, are provided as furnished information and are not deemed filed for liability purposes under the securities laws.
ANI Pharmaceuticals furnished an updated investor presentation to the investor relations section of its website and attached it as Exhibit 99.1. The presentation is dated November 2025 and may be used in meetings with investors, analysts, and others.
The materials were provided under Items 2.02 and 7.01 and are expressly designated as furnished, not filed, under the Exchange Act, and are not subject to Section 18 liabilities or incorporated into other filings unless specifically referenced.
ANI Pharmaceuticals, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025. The company announced these results in a press release dated November 7, 2025, which is included as Exhibit 99.1. The report clarifies that the information about these quarterly results is being furnished rather than filed, meaning it is not subject to certain liability provisions under securities law unless specifically incorporated into other filings.
ANI Pharmaceuticals, Inc. disclosed that all of its Series A Convertible Preferred Stock held by Ampersand 2020 Limited Partnership has been converted into common stock. Ampersand originally purchased 25,000 Preferred Shares in 2021 for an aggregate $25 million, with the shares carrying a 6.50% cumulative dividend and conversion features set out in a Certificate of Designation.
On August 14, 2025, Ampersand optionally converted 5,000 Preferred Shares into 120,580 common shares at a conversion price of $41.4662 per share. On September 26, 2025, after specified stock price conditions were met, ANI mandatorily converted the remaining 20,000 Preferred Shares into 482,320 common shares at the same conversion price.
In total, the conversions exchanged all 25,000 Preferred Shares for 602,900 common shares, leaving no Preferred Shares outstanding. The common shares issued in these exchanges relied on the Section 3(a)(9) exemption under the Securities Act for transactions with existing security holders without paid solicitation.
ANI Pharmaceuticals, Inc. filed a current report noting that President & CEO Nikhil Lalwani and the executive leadership team will present at two upcoming investor conferences in New York City. They are scheduled to speak at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025.
The company prepared an updated investor presentation for these events, dated September 2025, and may use it in future meetings with investors and analysts. This presentation is provided as Exhibit 99.1 and is furnished, rather than filed, meaning it is not subject to certain liability provisions under securities laws unless specifically incorporated into other filings.
ANI Pharmaceuticals, Inc. furnished an earnings press release covering its financial results for the second quarter ended June 30, 2025. The company disclosed that it issued this press release on August 8, 2025, and attached it as Exhibit 99.1 to the report. The information related to these results is being furnished rather than filed under securities laws, which means it is not automatically subject to certain liability provisions or incorporated into other regulatory filings unless specifically referenced.